SEC Form CERT filed by VG Acquisition Corp.

Record Year-to-Date Total Debt and Equity Commitments of $971.7 Million Record Year-to-Date Total Fundings of $634.0 Million Surpassed $12.0 Billion in Cumulative Total Debt Commitments since Inception Q2 2021 Net Asset Value per Share Increased 3.1% to $11.71 from Q1 2021 Record Undistributed Earnings Spillover of $160.2 Million, or $1.38(1) per Ending Shares Outstanding Q2 2021 Financial Achievements and Highlights Net Investment Income "NII" of $37.0 million, or $0.32 per share, an increase of 3.6% year-over-year Total Investment Income of $69.6 million, an increase of 2.3% year-over-year Total gross new debt and equity commitments of $440.8 million Net Hercules' debt and e

SUNNYVALE, Calif. and NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- 23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company sponsored by Virgin Group, today announced the completion of their previously announced business combination. The transaction, which was approved on June 10, 2021 by VG Acquisition Corp.'s shareholders, uniquely positions 23andMe to revolutionize personalized healthcare and therapeutic development through human genetics. The combined company is called 23andMe Holding Co. and will be traded on The Nasdaq Global Select Market ("Nasdaq") beginning on June 17, 2021 under the new ticker symb

NEW YORK, June 10, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group ("VGAC" or the "Company") today announced that its shareholders voted to approve the previously announced merger agreement with 23andMe, Inc. ("23andMe") at VGAC's extraordinary general meeting of shareholders (the "Special Meeting") held earlier today. More than 87% of the votes cast at the Special Meeting were in favor of the approval of the merger agreement.  VGAC shareholders also voted overwhelmingly to approve the other proposals presented at the Special Meeting. As previously announced, the consummation of the business combination with 23andMe is